Literature DB >> 15129775

The relation between latent inhibition and symptom-types in young schizophrenics.

Efrat Cohen1, Noam Sereni, O Kaplan, A Weizman, L Kikinzon, I Weiner, R E Lubow.   

Abstract

Latent inhibition (LI), retarded conditioning to a stimulus that has been previously repeatedly presented without reinforcement, was examined in young schizophrenics and normal controls using a within-subject visual search task. Healthy controls exhibited the usual LI effect. LI was potentiated in schizophrenics who simultaneously exhibited high levels of negative symptoms and low levels of positive symptoms. Schizophrenic groups with other combinations of positive and negative symptoms did not differ from controls. The pattern of data suggests that past inconsistencies in the LI-schizophrenia literature may be the result of opposing processes that are associated with positive and negative symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15129775     DOI: 10.1016/s0166-4328(03)00221-3

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  13 in total

1.  The neuromodulator of exploration: A unifying theory of the role of dopamine in personality.

Authors:  Colin G Deyoung
Journal:  Front Hum Neurosci       Date:  2013-11-14       Impact factor: 3.169

2.  The visual search analogue of latent inhibition: implications for theories of irrelevant stimulus processing in normal and schizophrenic groups.

Authors:  R E Lubow; Oren Kaplan
Journal:  Psychon Bull Rev       Date:  2005-04

3.  Behavioral predictors of alcohol drinking in a neurodevelopmental rat model of schizophrenia and co-occurring alcohol use disorder.

Authors:  Jibran Y Khokhar; Travis P Todd
Journal:  Schizophr Res       Date:  2017-03-09       Impact factor: 4.939

4.  Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.

Authors:  Byron K Y Bitanihirwe; Daria Peleg-Raibstein; Forouhar Mouttet; Joram Feldon; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

5.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

7.  Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered.

Authors:  I Gaisler-Salomon; L Diamant; C Rubin; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  2007-10-11       Impact factor: 4.530

8.  Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.

Authors:  Viviane Labrie; Tatiana Lipina; John C Roder
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

9.  Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.

Authors:  V Labrie; W Wang; S W Barger; G B Baker; J C Roder
Journal:  Genes Brain Behav       Date:  2009-08-05       Impact factor: 3.449

10.  Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action.

Authors:  Cecilie Bay-Richter; Colm M P O'Tuathaigh; Gerard O'Sullivan; David M Heery; John L Waddington; Paula M Moran
Journal:  Int J Neuropsychopharmacol       Date:  2008-11-17       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.